Distinguished in HIV/AIDS

Dr. Marina F. Caskey

Infectious Disease
Weill Medical College Of Cornell
525 E 68th St, 
New York, NY 
Distinguished in HIV/AIDS
Weill Medical College Of Cornell
525 E 68th St, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marina Caskey is an Infectious Disease provider in New York, New York. Dr. Caskey is rated as a Distinguished provider by MediFind in the treatment of HIV/AIDS. Her top areas of expertise are HIV/AIDS, Severe Acute Respiratory Syndrome (SARS), Sepsis, and Pneumonia.

Her clinical research consists of co-authoring 121 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 67 articles and participated in 6 clinical trials in the study of HIV/AIDS.

Specialties
Infectious Disease
Licenses
Internal Medicine in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

WEILL MEDICAL COLLEGE OF CORNELL
525 E 68th St, New York, NY 10065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An Open Label, Randomized Study of the Safety and Antiretroviral Activity of 3BNC117 and 10-1074 in HIV-infected Individuals on Combination Antiretroviral Therapy and During Analytical Treatment Interruption.
An Open Label, Randomized Study of the Safety and Antiretroviral Activity of 3BNC117 and 10-1074 in HIV-infected Individuals on Combination Antiretroviral Therapy and During Analytical Treatment Interruption.
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Other, Drug
Study Drugs: 3BNC117, 10-1074
Study Phase: Phase 1
An Open Label, Single Arm Study of the Safety, Pharmacokinetics and Antiretroviral Activity of the Combination of 3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals.
An Open Label, Single Arm Study of the Safety, Pharmacokinetics and Antiretroviral Activity of the Combination of 3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals.
Enrollment Status: Completed
Publish Date: June 26, 2023
Intervention Type: Drug
Study Drugs: 3BNC117-LS, 10-1074-LS
Study Phase: Phase 1
A Phase 2a, Randomized Study of Romidepsin With or Without 3BNC117 to Evaluate the Effects on the HIV-1 Reservoir (ROADMAP)
A Phase 2a, Randomized Study of Romidepsin With or Without 3BNC117 to Evaluate the Effects on the HIV-1 Reservoir (ROADMAP)
Enrollment Status: Completed
Publish Date: July 14, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Dose Escalation, First-in-human Study of the Safety and Pharmacokinetics of the Subcutaneous and Intravenous Administration of 10-1074-LS Alone and in Combination With 3BNC117-LS in HIV-infected and HIV-uninfected Individuals
A Phase 1, Dose Escalation, First-in-human Study of the Safety and Pharmacokinetics of the Subcutaneous and Intravenous Administration of 10-1074-LS Alone and in Combination With 3BNC117-LS in HIV-infected and HIV-uninfected Individuals
Enrollment Status: Completed
Publish Date: August 04, 2021
Intervention Type: Drug
Study Drugs: 10-1074-LS, 3BNC117-LS
Study Phase: Phase 1
A Phase 1 First-in-human Study of the Safety and Pharmacokinetics of 3BNC117-LS in HIV-infected and HIV-uninfected Individuals
A Phase 1 First-in-human Study of the Safety and Pharmacokinetics of 3BNC117-LS in HIV-infected and HIV-uninfected Individuals
Enrollment Status: Completed
Publish Date: February 03, 2021
Intervention Type: Drug
Study Phase: Phase 1
An Phase 1b Study of the Safety, Pharmacokinetics and Antiretroviral Activity of the Combination of 3BNC117 and 10-1074 in HIV-infected Individuals
An Phase 1b Study of the Safety, Pharmacokinetics and Antiretroviral Activity of the Combination of 3BNC117 and 10-1074 in HIV-infected Individuals
Enrollment Status: Completed
Publish Date: August 21, 2018
Intervention Type: Other, Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

121 Total Publications

Distinct modes of evolution drive HIV escape from two broadly neutralizing antibodies.
Distinct modes of evolution drive HIV escape from two broadly neutralizing antibodies.
Journal: bioRxiv : the preprint server for biology
Published: September 05, 2025
Similar Doctors
Wafaa M. El-Sadr
Elite in HIV/AIDS
Dr. Wafaa M. El-Sadr
Infectious Disease
Elite in HIV/AIDS
Dr. Wafaa M. El-Sadr
Infectious Disease
506 Malcolm X Blvd, Wp-522, 
New York, NY 
 (3.5 miles away)
212-939-2740
Languages Spoken:
English
See accepted insurances

Wafaa El-Sadr is an Infectious Disease provider in New York, New York. Dr. El-Sadr is rated as a Distinguished provider by MediFind in the treatment of HIV/AIDS. Her top areas of expertise are HIV/AIDS, COVID-19, Severe Acute Respiratory Syndrome (SARS), and Ebola Virus Disease.

Elite in HIV/AIDS
Dr. Jihad S. Slim
Infectious Disease
Elite in HIV/AIDS
Dr. Jihad S. Slim
Infectious Disease

Njcri Physicians Group PC

393 Central Ave, 
Newark, NJ 
 (12.3 miles away)
973-483-3444
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jihad Slim is an Infectious Disease provider in Newark, New Jersey. Dr. Slim is rated as a Distinguished provider by MediFind in the treatment of HIV/AIDS. His top areas of expertise are HIV/AIDS, Hepatitis C, COVID-19, Hepatitis, and Gastrostomy.

Judith A. Aberg
Elite in HIV/AIDS
Dr. Judith A. Aberg
Infectious Disease
Elite in HIV/AIDS
Dr. Judith A. Aberg
Infectious Disease

Icahn School Of Medicine At Mount Sinai

17 E 102nd St, 
New York, NY 
 (1.9 miles away)
212-659-8551
Languages Spoken:
English
See accepted insurances

Judith Aberg is an Infectious Disease provider in New York, New York. Dr. Aberg is rated as a Distinguished provider by MediFind in the treatment of HIV/AIDS. Her top areas of expertise are HIV/AIDS, COVID-19, Severe Acute Respiratory Syndrome (SARS), and Vitamin D Deficiency.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Caskey's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile